Lastly, increased pre-transplant levels of ST2 indicate a higher risk of TA-TMA (95) and, when measured at day +28, can be useful in predicting the likelihood of GvHD, together with non-relapse mortality and overall survival (125). This evidence concerns the gene IL1RL1 and graft versus host disease.